Navigation Links
SAGE Labs, Inc. Licenses CRISPR/Cas9 genome engineering technology from Caribou Biosciences, Inc.

ST. LOUIS, Sept. 24, 2013 /PRNewswire/ -- SAGE Labs, Inc., a leading provider of in vivo products, services and technologies in the field of genome engineering, announced today that it has entered into a partnership and licensing agreement with Caribou Biosciences, Inc. (Caribou Bio) for key intellectual property related to the CRISPR/Cas9 genome editing system.

Under the agreement, SAGE Labs will gain exclusive rights to Caribou Bio's intellectual property to produce and sell genetically engineered rats, and will gain non-exclusive rights for mouse and rabbit models.  The Cas9 system will complement SAGE's Zinc Finger Nuclease (ZFN) technology, allowing SAGE to offer customers access to novel animal models of human disease, as well as reduced turnaround times for its custom model creation platform, SAGEspeed®.

"SAGE Labs is the leader in creation of next-generation research models. As such, it is important to have access to key technologies needed to perform complex genome engineering projects," commented Dr. David Smoller, CEO of SAGE Labs. "Using Cas9 allows us to provide our customers with enhanced models that provide the most translational value for their research."

"We believe the Cas9 system will become very important in the creation of new models of human disease, both in vitro and in vivo," commented Dr. Rachel Haurwitz, CEO of Caribou Bio. "SAGE Labs' track record as a market leader in commercializing in vivo technologies will enable them to use Cas9-based engineering to bring innovative, high-quality engineered research models to the marketplace."

Please see for further details.

About SAGE Labs

SAGE® Labs is a world-class provider of next-generation research models and transgenic support services. Using proprietary platform technologies, such as Zinc Finger Nucleases (ZFN) and the CRISPR/Cas9 system for genome engineering, SAGE produces complex in vivo research models in half the time as models produced using conventional technologies. For more information, visit

About Caribou Bio

Caribou Bio specializes in the research and development of technologies for cellular engineering and analysis. Caribou Bio's technologies are based on the unique capabilities of Cas enzymes from the CRISPR prokaryotic immune system. Caribou Bio's lead technology is the Cas9 enzyme, a highly efficient and easy to use genome editing platform that does not require unique protein development.

Media Contact:
Phil Simmons
(314) 313-7847


Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. LABS, Inc. Earns AABB Accreditation for Donor Testing
2. LABS, Inc. Among Colorados Top Private Companies
3. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
4. Sigma Life Science Licenses CompoZr Zinc Finger Nuclease Technology to Horizon Discovery
5. Genomatica Licenses TeselaGen Software for DNA Design
6. Empire Genomics Licenses Novel DNA Biomarker for Use in Diagnosing and Creating a Companion Diagnostic Test for Neuroendocrine Prostate Cancer
7. SRI International Licenses Bed Bug Detection Technology to Redcoat, a Virginia-Based Start-Up Company
8. Personal Genome Diagnostics Inc. Licenses Genome-Mapping Technology from Johns Hopkins University and Expands Its Cancer Genome Analysis Business
9. Genomas Expands Personalized Medicine Business with Clinical Laboratory Licenses in New York, Florida, California
10. Syngenta Licenses Plant Sensory Systems' Technology
11. Bluechiip Licenses Its Technology in Deal with US Tech Company MiTeGen
Post Your Comments:
(Date:11/24/2015)... , Nov. 24, 2015 According to two new ... 2005. This is something that many doctors, scientists, and public ... questions remains: with fewer PSA tests being done, will there ... Dr. David Samadi, "Despite the efforts made ... remains the second leading cancer cause of death in men, ...
(Date:11/23/2015)... HONG KONG, Nov. 23, 2015 China Cord ... "Company"), China,s leading provider of cord blood collection, laboratory ... services, today announced its preliminary unaudited financial results for ... 2016 ended September 30, 2015. --> ... Highlights , Revenues for the second quarter of ...
(Date:11/23/2015)... 23, 2015 The royalty-free a ... to develop daclatasvir for 112 low- and ... --> --> The Medicines Patent ... C medicine, signing an agreement with Bristol-Myers Squibb for daclatasvir, ... multiple genotypes of the HCV virus.  The royalty-free licence will ...
(Date:11/23/2015)... Nov. 23, 2015  CryoLife, Inc. (NYSE: CRY ), ... cardiac and vascular surgery, announced today that it will participate ... Conference on Wednesday, December 2, 2015 at The New York ... Pat Mackin , President and Chief Executive Officer. ... Executive Officer. --> A live webcast of ...
Breaking Biology Technology:
(Date:11/9/2015)... ) ... "Global Law Enforcement Biometrics Market 2015-2019" ... ) has announced the addition of ... 2015-2019" report to their offering. ... ) has announced the addition of the ...
(Date:11/4/2015)... 2015 --> ... by Transparency Market Research "Home Security Solutions Market - Global ... - 2022", the global home security solutions market is expected to ... The market is estimated to expand at a CAGR ... 2022. Rising security needs among customers at homes, the ...
(Date:10/29/2015)... Minn. , Oct. 29, 2015   MedNet ... supports the entire spectrum of clinical research, is pleased ... Minnesota High Tech Association (MHTA) as one of only ... in the "Software – Small and Growing" category. The Tekne ... individuals who have shown superior technology innovation and leadership. ...
Breaking Biology News(10 mins):